Papua New GuineaTuberculosis profile
Population  2015 7.6 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.1 (1.8–4.6) 40 (24–61)
Mortality (HIV+TB only) 0.67 (0.4–1) 8.8 (5.2–13)
Incidence  (includes HIV+TB) 33 (27–40) 432 (352–521)
Incidence (HIV+TB only) 4.9 (3–7.3) 64 (39–96)
Incidence (MDR/RR-TB)** 1.9 (1.2–2.5) 25 (16–33)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 2 (1.1–2.9) 14 (11–18) 16 (12–21)
Males 1.6 (0.99–2.2) 15 (12–19) 17 (13–21)
Total 3.6 (2.4–4.8) 29 (26–33) 33 (27–40)
TB case notifications, 2015  
Total cases notified 28 696
Total new and relapse 26 347
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 36%
          - % pulmonary 54%
          - % bacteriologically confirmed among pulmonary 31%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (66–98)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.11 (0.07–0.17)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 758 8%
          - on antiretroviral therapy 494 65%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 100
(800–1 500)
Estimated % of TB cases with MDR/RR-TB 3.4% (1.7–5) 26% (15–36)  
% notified tested for rifampicin resistance     1 895
MDR/RR-TB cases tested for resistance to second-line drugs   147
Laboratory-confirmed cases MDR/RR-TB: 254, XDR-TB: 11
Patients started on treatment **** MDR/RR-TB: 225, XDR-TB: 11
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 70% 4 077
Previously treated cases registered in 2014 63% 728
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 11
Funding source:  domestic, 100% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data